Sharda School of Pharmacy, Pethapur, Gandhinagar, Gujarat – 382610
Materiovigilance (Mv) plays a vital role in safeguarding patient health, much like pharmacovigilance—yet its focus is on medical devices. It involves the identification, reporting, and monitoring of medical device–associated adverse events (MDAEs) to ensure devices used in healthcare remain safe, reliable, and effective. Through continuous safety surveillance, Mv has enabled the timely recall of defective, malfunctioning, or unsafe devices, thereby preventing serious patient harm. It encourages the reporting of all types of events—whether serious or minor, expected or unexpected, frequent or rare, or even those linked to devices with incomplete specifications. Every report contributes to a deeper understanding of device performance. By gathering real-world safety data, Mv helps enhance device design, functionality, and overall efficiency, minimizing complications and failures. It also raises alarms about counterfeit, substandard, or poor-quality devices, protecting both healthcare workers and patients. Continuous reporting of medical device-associated adverse events (MDAEs), whether critical or minor, known or unknown, frequent or rare, contributes to timely identification of defective or malfunctioning devices. This process has supported several global devices recalls and has strengthened patient protection. Commonly reported issues include device breakage or malfunction, infections at insertion sites, organ injuries, device-related surgeries, and even fatalities. Many global health authorities have established structured MDAE reporting systems with clear timelines—such as MedWatch (USA) and MedSafe (New Zealand).To ensure safer healthcare, both professionals and consumers must understand the importance of Mv, know how to report device-related problems, and be aware of action steps when adverse events occur. Materiovigilance ultimately strengthens trust in medical devices and supports a safer healthcare environment for all.
Technological progress has greatly transformed healthcare practices and contributed to significantly better patient outcomes. Recent innovations-such as drug-device combination technologies, automation and robotics, and increasingly sophisticated medical equipment- have rapidly expanded the use of medical devices across healthcare facilities (HCFs). These devices play a crucial role in diagnosing, preventing, and treating a wide range of conditions and they include everything from simple metered-dose inhalers to highly complex radiology and operating room equipment [1].
Globally, the demand for medical devices has increased sharply, rising from 260 billion USD in 2006 to 380 billion USD in 2016. This growth correlates with the rising prevalence of chronic diseases such as stroke, obesity, diabetes, cancer, and others . Consequently, with every new device entering the market, it becomes essential for healthcare providers, policymakers, regulators, and patients to understand its safety, effectiveness, quality standards, and other critical parameters-areas traditionally explored through long-term pharmacovigilance (Pv). Applying similar principles to medical devices has led to the development of materiovigilance (Mv) [2].
With the expanding utilization of medical devices, concerns regarding their safety have also intensified. As with pharmaceuticals, post-marketing evidence is essential to evaluate device performance and identify safety issues . Although adverse events are routinely documented during mandatory phases I-III clinical trials, reporting becomes voluntary during the post-marketing (phase IV) period, where underreporting remains common . Moreover, many adverse events cannot be fully captured during pre-market evaluations due to intrinsic limitations of clinical trials. Thus, healthcare professionals and regulators rely heavily on long-term spontaneous reporting by practitioners and patients . In response, several device manufacturers have implemented continuous ("living") data-mining systems to ensure timely detection of emerging safety concerns[3].
The rapid advancement of medical technology has led to a substantial increase in the use of medical devices across healthcare systems worldwide. These devices, ranging from simple consumables to complex diagnostic and therapeutic equipment, play a vital role in disease prevention, diagnosis, monitoring, and treatment. As their use becomes increasingly widespread, ensuring their safety, quality, and performance has emerged as a critical public health priority[4].
To address these challenges, the concept of materiovigilance (Mv) has evolved as a dedicated system for the systematic monitoring, assessment, reporting, and prevention of adverse events or malfunctions associated with medical devices. Modeled on the principles of pharmacovigilance, materiovigilance focuses on generating evidence from real-world use to enhance device safety and support regulatory decision-making throughout the device life cycle [5].
Given that pre-market evaluations and clinical trials have inherent limitations in detecting all potential risks, robust post-marketing surveillance has become essential[6].
Materiovigilance programs aim to bridge this gap by encouraging spontaneous reporting from healthcare professionals, manufacturers, and patients, thereby facilitating early identification of device-related risks, timely corrective actions, and overall improvement in patient safety[7].
As global healthcare continues to adopt increasingly sophisticated technologies, the establishment and strengthening of materiovigilance systems are indispensable for ensuring the safe and effective use of medical devices and for maintaining public trust in modern healthcare innovations[8].
PHARMACOVIGILANCE AND EMERGENCE OF MATERIOVIGILANCE :
Pharmacovigilance (Pv) is the scientific discipline focused on the continuous detection, assessment, evaluation, and prevention of both acute and chronic adverse reactions associated with newly introduced as well as existing medicines. In recent years, the scope of Pv has expanded to include drug therapy-related problems arising from herbal, traditional, complementary, and alternative medicines (TCAMs), biological products, blood-derived products, vaccines, and even certain medical devices. Pharmacoepidemiological studies are increasingly utilized to assess the real-world safety and effectiveness of therapeutic agents[9].
Materiovigilance (Mv), while sharing similar objectives and reporting methodologies with Pv, specifically addresses the monitoring and prevention of adverse events related to medical devices. Such events may occur due to device design or manufacturing defects, inadequate maintenance, improper storage or logistics, insufficient user training, incorrect or off-label use, or other contextual factors. As with medicines, medical devices also carry inherent risks. Therefore, systematic surveillance of device safety is essential to identify, correct, or remove faulty or potentially harmful devices from the market, thereby enhancing their quality and performance[10].
GLOBAL MATERIOVIGILANCE INITIATIVES :
The International Medical Device Regulators Forum (IMDRF), established in 2011 and consisting of ten member countries including the USA, Japan, the European Union, China, South Korea, and India, aims to promote the concept and implementation of materiovigilance (Mv). Its primary objectives are to monitor medical device-related adverse events (MDAEs) and to harmonize global regulatory practices related to medical devices[11].
India's Materiovigilance Programme (MvPI), launched on July 6, 2015, plays a crucial role in systematically collecting safety data on medical device use across the country. The program focuses on monitoring MDAEs, increasing awareness and reporting among healthcare professionals, evaluating benefit-risk profiles, generating evidence-based safety recommendations, and communicating these findings to stakeholders and regulatory bodies[12].
Several countries have established strong post-market surveillance systems[13]:
United States
FDA's MAUDE database monitors device issues. It has led to numerous recalls and safety alerts.
European Union
The EU Medical Device Regulation (EU MDR) introduced tighter vigilance requirements, including traceability and post-market clinical follow-up (PMCF).
India
The Materiovigilance Program of India (MvPI) was launched in 2015, coordinating nationwide reporting through hospitals, manufacturers, and laboratories.
Global Collaboration
International Medical Device Regulators Forum (IMDRF) harmonizes standards and reporting systems globally.
SIGNIFICANCE OF MATERIOVIGILANCE
Materiovigilance (Mv) has evolved as an expanded and specialized extension of pharmacovigilance aimed at enhancing patient safety by reducing the occurrence of medical device-associated adverse events (MDAEs). It establishes a national framework for continuous patient-safety monitoring, generates evidence-based data on device safety, evaluates risk-benefit profiles, and disseminates this information to relevant stakeholders. Mv further supports regulatory authorities by facilitating informed decision-making, promoting collaboration with national and international bodies for MDAE reporting and investigation, and helping prevent future adverse events[14].
In clinical settings, Mv assists healthcare providers in diagnosing, monitoring, managing, and mitigating device-related complications. It also enables manufacturers to refine device design and performance, conduct life-cycle assessments, and ensure robust reporting of adverse events. This is essential to prevent issues related to counterfeit or substandard devices, such as device breakage, malfunction, infections at insertion or removal sites, organ injury or perforation, the need for surgical intervention, and, in severe cases, death[15].
CAUSES AND TYPES OF MEDICAL DEVICE FAILURES[16]
Device failures may arise at any stage-from design to disposal.
Categories of Device Failures
Commonly Affected Devices
Infusion pumps, Orthopedic implants, Cardiac pacemakers and stents, Surgical instruments, Diagnostic devices (IVDs),Ventilators and life-support equipment.
Challenges in Implementing Materiovigilance:
Despite growing recognition, barriers remain:
Overcoming these challenges is necessary for a safer healthcare environment.
TRANSITION FROM DEVICE FAILURE TO SAFETY REFORM[17].
Materiovigilance has become a major driver of reforms:
Improved Device Design
Surveillance data guides manufacturers in strengthening: Materials, Ergonomics, Software safety, Battery performance
Stronger Regulatory Standards
Countries have introduced: More rigorous premarket testing, Mandatory post-market surveillance, Stricter quality audits
Better Clinical Practice
Hospitals implement: Device-use protocols, Regular maintenance schedules, Training for users, Real-time reporting culture
Increased Transparency
Public databases allow patients and clinicians to access safety alerts, increasing trust.
FUTURE DIRECTIONS: DIGITAL AND AL-DRIVEN MATERIOVIGILANCE[18].
Emerging innovations include:
WHO CAN REPORT IN MATERIOVIGILANCE[19]?
HOW TO REPORT? [20].
WHAT HAPPENS AFTER REPORTING[21]?
Once submitted:
Helpline number Mobile app
FIGURE – 1: MEDICAL DEVICE ADVERSE EVENT REPORTING FORM[22].
FIGURE – 1: MEDICAL DEVICE ADVERSE EVENT REPORTING FORM
FIGURE – 1: MEDICAL DEVICE ADVERSE EVENT REPORTING FORM
RESULT :
The review of global materiovigilance systems shows that structured medical device surveillance significantly enhances patient safety and regulatory oversight. Countries with active reporting programs, such as the FDA’s MAUDE database, the EU’s MDR vigilance system, and India’s MvPI, consistently demonstrate higher detection rates of medical device–associated adverse events, indicating improved awareness and reporting practices among healthcare professionals. Evidence shows that timely surveillance interventions—such as device recalls, software corrections, updated labeling, and corrective and preventive actions—have contributed to a reduction in serious device-related injuries, diagnostic errors, and treatment delays. Regulatory bodies have strengthened their frameworks based on materiovigilance data, leading to more stringent device approval processes, enhanced traceability through Unique Device Identification (UDI), and increased transparency through public safety alerts. Hospitals participating in materiovigilance networks report improved staff training, better device maintenance and calibration practices, and more frequent documentation of near-miss incidents. Manufacturers have also benefited from feedback generated through surveillance systems, allowing them to redesign devices, address real-world use problems, and enhance long-term reliability. Additionally, patient involvement through direct reporting has improved early detection of implant failures and increased awareness about device safety. Overall, the evidence suggests that materiovigilance transforms medical device safety from a reactive, post-harm approach to a proactive, preventive system that strengthens healthcare quality and reduces risks across clinical environments.
CONCLUSION :
Materiovigilance has emerged as a critical component of modern healthcare systems, ensuring that medical devices remain safe, effective, and reliable throughout their entire lifecycle. As device use continues to expand—from simple disposables to complex implantable technologies—the potential for failures, malfunctions, and user-related errors increases, making structured surveillance more essential than ever. The evidence shows that materiovigilance not only enables early detection of device-associated adverse events but also drives significant safety reforms through corrective and preventive actions, regulatory strengthening, improved reporting culture, and enhanced patient awareness. By fostering collaboration between healthcare professionals, manufacturers, regulators, and patients, materiovigilance transforms medical device safety from a reactive approach to a proactive and preventive system. Moving forward, the integration of digital technologies, artificial intelligence, and real-time monitoring will further strengthen this framework, ensuring a safer healthcare environment and improved patient outcomes. Ultimately, a robust materiovigilance system is not just a regulatory requirement—it is a cornerstone of patient safety and quality medical care.
REFERENCES
Jeel Mevada, Kashish Patel, Amar Raval, Materiovigilance: From Device Failure to Safety Reform, The Growing Importance of Materiovigilance Systems, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 1, 962-974. https://doi.org/10.5281/zenodo.18207625
10.5281/zenodo.18207625
